Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cellss

Molecular Pharmacology

Volumn 87, Issue 6, 2015, Pages 1006-1012

  Fernandez, Elena V ^a   Reece, Kelie M ^a   Ley, Ariel M ^a   Troutman, Sarah M ^a   Sissung, Tristan M ^a   Price, Douglas K ^a   Chau, Cindy H ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ENZALUTAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; VASCULOTROPIN; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; CHETOMIN; COBALT; COBALT CHLORIDE; DISULFIDE; INDOLE ALKALOID; PHENYLTHIOHYDANTOIN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; DRUG EFFECTS; GENETICS; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; COBALT; DIHYDROTESTOSTERONE; DISULFIDES; DRUG SYNERGISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLE ALKALOIDS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84940214207     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097477     Document Type: Article

References (26)

1. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, and Scher H et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586.
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
3. Debes JD and Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488-1490.
4. Ghafar MA, Anastasiadis AG, Chen MW, Burchardt M, Olsson LE, Xie H, Benson MC, and Buttyan R (2003) Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 54:58-67.
5. Greer SN, Metcalf JL, Wang Y, and Ohh M (2012) The updated biology of hypoxia-inducible factor. EMBO J 31:2448-2460.
6. Guerrero J, Alfaro IE, Gómez F, Protter AA, and Bernales S (2013) Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73:1291-1305.
7. Halin S, Hammarsten P, Wikström P, and Bergh A (2007) Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 67:370-377.
8. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, Sakaue M, Sano T, Kitagawa T, and Himeno S et al. (2007) Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 5:383-391.
9. Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, Chandhoke R, Meacham RB, and Koul HK (2009) Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28:1248-1260.
10. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, and Wang J et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33-43.
11. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, and Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73:483-489.
12. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, and Simons JW (2003) Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 39-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9:2416-2425.
13. Mitani T, Harada N, Nakano Y, Inui H, and Yamaji R (2012) Coordinated action of hypoxia-inducible factor-1α and β-catenin in androgen receptor signaling. J Biol Chem 287:33594-33606.
14. Mitani T, Yamaji R, Higashimura Y, Harada N, Nakano Y, and Inui H (2011) Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment. J Steroid Biochem Mol Biol 123:58-64.
15. Nelson WG and Yegnasubramanian S (2013) Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov 3:971-974.
16. Park C, Kim Y, Shim M, and Lee Y (2012) Hypoxia enhances ligand-occupied androgen receptor activity. Biochem Biophys Res Commun 418:319-323.
17. Pienta KJ and Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665-1671.
18. Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, Baldwin G, and Patel O (2014) The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med 3:245-251.
19. Scher HI and Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261.
20. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
21. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408.
22. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, and Buttyan R (2001) Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 81:437-444.
23. Sharifi N, Hurt EM, Thomas SB, and Farrar WL (2008) Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin Cancer Res 14: 6073-6080.
24. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, and Riddick AC (2010) The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105:8-13.
25. Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, and Zoubeidi A (2014) Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. Eur Urol, in press.
26. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, and Kwon A et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790.